. 2021 Mar 31;143:155523. doi: 10.1016/j.cyto.2021.155523

Table 4.

Univariate analysis of the impact of possible risk factors on overall survival and event-free survival (EFS) in critically sever and severe patients P-Value.

Variable	No. of Patients	Mean (days ± SD)	P Value
Overall survival
Sex
male	31	44.18 ± 4.17	0.237
female	10	47.80 ± 2.86	0.237
Age
Low(<median)	19	43.92 ± 2.85	0.46
High(>median)	22	46.60 ± 4.38	0.46
Comorbidities
without	15	35.01 ± 1.40	0.406
with	26	47.98 ± 4.17	0.406
IL-6
Low(<median)	20	37.50 ± 0.31	0.13
High(>median)	21	43.82 ± 3.60	0.13
IL-10
Low(<median)	20	42.75 ± 1.21	0.02
High(>median)	21	40.84 ± 4.17	0.02
IL-6 + IL-10
Two positive	20	39.14 ± 4.31	0.01
other	21	49.31 ± 1.63	0.01
CD3 + Cnt
Low(<median)	14	52.10 ± 4.03	0.62
High(>median)	16	46.55 ± 2.68	0.62
CD3 + CD8 + Cnt
Low(<median)	15	49.62 ± 4.36	0.25
High(>median)	15	48.71 ± 2.12	0.25
EFS
Sex
male	44	20.05 ± 2.06	0.054
female	27	29.88 ± 3.03	0.054
Age
Low(<median)	35	29.11 ± 2.63	0.02
High(>median)	36	20.12 ± 2.60	0.02
Comorbidities
without	34	29.38 ± 2.70	0.02
with	37	18.91 ± 2.23	0.02
IL-6
Low(<median)	34	34.69 ± v2.13	<0.001
High(>median)	37	14.54 ± 1.94	<0.001
IL-10
Low(<median)	35	33.14 ± 2.25	<0.001
High(>median)	36	15.41 ± 2.22	<0.001
IL-6 + IL-10
Two positive	21	8.10 ± 0.77	<0.001
other	50	31.11 ± 2.07	<0.001
CD3 + Cnt
Low(<median)	14	11.29 ± 1.81	0.72
High(>median)	16	13.19 ± 2.38	0.72
CD3 + CD8 + Cnt
Low(<median)	15	10.13 ± 1.32	0.21
High(>median)	15	15.07 ± 2.93	0.21

P Value < 0.05 was considered statistically significant. Data were available for 71 patients. IL-6: interleukin-6; IL-6 + IL-10: interleukin-6 and interleukin-10 positive;CD3 + Cnt: absolute T lymphocyte count; CD3 + CD8 + Cnt: inhibitory/cytotoxic T lymphocyte absolute count.